Trial Profile
A 5-year, long-term, Italian multicentre, randomised trial evaluating deferiprone versus deferoxamine in sickle cell disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary) ; Deferoxamine
- Indications Iron overload; Sickle cell anaemia
- Focus Therapeutic Use
- 27 Nov 2015 New trial record